1. Home
  2. CXH vs ALXO Comparison

CXH vs ALXO Comparison

Compare CXH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Investment Grade Municipal Trust

CXH

MFS Investment Grade Municipal Trust

HOLD

Current Price

$8.24

Market Cap

66.4M

Sector

Finance

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.97

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXH
ALXO
Founded
1989
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
68.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CXH
ALXO
Price
$8.24
$1.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.00
AVG Volume (30 Days)
22.8K
721.1K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
3.56%
N/A
EPS Growth
N/A
26.36
EPS
0.23
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$0.41
52 Week High
$8.39
$2.66

Technical Indicators

Market Signals
Indicator
CXH
ALXO
Relative Strength Index (RSI) 52.80 45.26
Support Level $8.11 $1.41
Resistance Level $8.39 $2.31
Average True Range (ATR) 0.05 0.19
MACD -0.00 -0.06
Stochastic Oscillator 31.41 1.45

Price Performance

Historical Comparison
CXH
ALXO

About CXH MFS Investment Grade Municipal Trust

Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: